Healthcare · Drug Manufacturers General · NASDAQ
| Market cap | $165.17B |
|---|---|
| Trailing P/E | — |
| FCF yield | 5.7% |
| Revenue growth (YoY) | +2.4% |
| EPS growth (YoY) | +76.8% |
| FCF/share growth (YoY) | -8.2% |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
Gilead Sciences, Inc. trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →
| Member | Chamber | Trade | Amount | Disclosed |
|---|---|---|---|---|
| Jared Moskowitz | House | Buy | $1,001 - $15,000 | May 31, 2026 |
| Valerie Hoyle | House | Sell | $1,001 - $15,000 | Sep 23, 2025 |
| Valerie Hoyle | House | Buy | $1,001 - $15,000 | Sep 11, 2025 |
| Marjorie Taylor Greene | House | Buy | $1,001 - $15,000 | May 6, 2025 |
| Carol Devine Miller | House | Buy | $1,001 - $15,000 | Apr 11, 2025 |
| Josh Gottheimer | House | Buy | $1,001 - $15,000 | Apr 4, 2025 |
| Greg Stanton | House | Buy | $1,001 - $15,000 | Oct 21, 2023 |
| Daniel Goldman | House | Sell | $15,001 - $50,000 | Aug 8, 2023 |
| Zoe Lofgren | House | Sell | $1,001 - $15,000 | Jun 6, 2023 |
| Daniel Goldman | House | Buy | $15,001 - $50,000 | Apr 3, 2023 |
| Sara Jacobs | House | Sell | $15,001 - $50,000 | May 11, 2021 |
| Gilbert Cisneros | House | Sell | $1,001 - $15,000 | Jan 8, 2021 |